Siemens joins Cleveland's Global Center for Health Innovation

Siemens Healthcare is the 20th tenant-partner of the Global Center for Health Innovation in Cleveland. 

The Siemens suite in the Global Center is outfitted with extensive virtual imaging and diagnostic capabilities, and a new learning and collaboration space that will give technicians the opportunity to train on state-of-the art equipment. Siemens will use the space for educational symposia, collaborations, meetings, a virtual sales center and to showcase its technology, according to a release.

“We are honored to have a powerhouse like Siemens Healthcare join our collaborative environment,” said Fred DeGrandis, managing director and chief administrative officer of the Global Center for Health Innovation. “Fresh, innovative thinking is what powers the Global Center, and Siemens executes this beautifully with its forward-thinking ideas--shedding light on what’s possible and inspiring innovation in healthcare.”

Cleveland is home to three of Siemens' "most significant research partners," said Terry Talbot, vice president and general manager of Central Zone, Siemens Healthcare North America--Case Western Reserve University, University Hospitals and The Cleveland Clinic. “Siemens Innovation comes from these outstanding partners and the knowledge workers that they provide.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.